{"id":72374,"date":"2026-08-12T13:54:39","date_gmt":"2026-08-12T05:54:39","guid":{"rendered":"https:\/\/flcube.com\/?p=72374"},"modified":"2026-08-12T13:54:40","modified_gmt":"2026-08-12T05:54:40","slug":"nmpa-approves-geneseeqs-fandekang-ntrk-fusion-detection-kit-as-companion-diagnostic-for-vcare-pharmatechs-eratrectinib","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72374","title":{"rendered":"NMPA Approves Geneseeq&#8217;s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech&#8217;s Eratrectinib"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>National Medical Products Administration (NMPA)<\/strong> approved <strong>Geneseeq Technology Inc.<\/strong>&#8216;s (a genetic cancer testing service provider operating in <strong>Canada and China<\/strong>) <strong>Fandekang NTRK1\/2\/3 gene fusion detection kit<\/strong> as a <strong>companion diagnostic (CDx)<\/strong> for <strong>eratrectinib<\/strong>, a <strong>next\u2011generation highly selective TRK inhibitor<\/strong> independently developed by <strong>Jiangsu Vcare PharmaTech Co., Ltd.<\/strong><\/p>\n\n\n\n<h2 id=\"h-approval-overview\" class=\"wp-block-heading\">Approval Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product Approved<\/strong><\/td><td>Fandekang NTRK1\/2\/3 gene fusion detection kit<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Companion diagnostic (CDx)<\/td><\/tr><tr><td><strong>Companion Drug<\/strong><\/td><td>Eratrectinib \u2014 next\u2011generation highly selective TRK inhibitor<\/td><\/tr><tr><td><strong>Drug Developer<\/strong><\/td><td>Jiangsu Vcare PharmaTech Co., Ltd.<\/td><\/tr><tr><td><strong>CDx Developer<\/strong><\/td><td>Geneseeq Technology Inc. (operating in Canada and China)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>6 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-diagnostic-profile\" class=\"wp-block-heading\">Diagnostic Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Detection Challenge Addressed:<\/strong> As the <strong>original CDx for eratrectinib<\/strong>, Fandekang addresses key detection challenges including the <strong>broad cross\u2011tumor distribution<\/strong>, <strong>low incidence<\/strong>, and <strong>complex fusion patterns<\/strong> of <strong>NTRK1\/2\/3 fusions<\/strong>.<\/li>\n\n\n\n<li><strong>Cross\u2011Tumor Capability:<\/strong> Enables <strong>accurate identification of NTRK fusion variants across different cancer types<\/strong> \u2014 critical for a tumor\u2011agnostic therapy like a TRK inhibitor.<\/li>\n\n\n\n<li><strong>Clinical Consistency Validated:<\/strong> <strong>Bridging studies<\/strong> demonstrated that patients who tested positive by Fandekang achieved <strong>objective response rates<\/strong> in both <strong>treatment\u2011na\u00efve and previously treated populations<\/strong> that were <strong>highly consistent with drug clinical trial results<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-context-amp-partnership\" class=\"wp-block-heading\">Drug Context &amp; Partnership<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Approval:<\/strong> Vcare&#8217;s <strong>eratrectinib was approved this June<\/strong> for the treatment of <strong>adult and adolescent (aged 12 and above) patients with solid tumors harboring NTRK fusion genes<\/strong>.<\/li>\n\n\n\n<li><strong>Long\u2011Standing Collaboration:<\/strong> <strong>Vcare PharmaTech and Geneseeq have a long\u2011standing collaborative relationship<\/strong>, with the CDx developed in parallel with the drug \u2014 a model that supports synchronized approval and clinical deployment.<\/li>\n\n\n\n<li><strong>Tumor\u2011Agnostic Pairing:<\/strong> The CDx approval completes the drug\u2011diagnostic pairing needed to identify eligible patients across tumor types under the tumor\u2011agnostic indication.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Oncology Infrastructure:<\/strong> NTRK fusions occur at low frequency across a wide range of solid tumors, making reliable pan\u2011cancer detection essential \u2014 Fandekang&#8217;s approval strengthens China&#8217;s precision oncology testing infrastructure.<\/li>\n\n\n\n<li><strong>TRK Inhibitor Competition:<\/strong> Eratrectinib enters the TRK inhibitor market alongside established agents, with diagnostic accuracy and patient identification becoming key competitive differentiators.<\/li>\n\n\n\n<li><strong>Cross\u2011Border Diagnostic Player:<\/strong> Geneseeq&#8217;s dual Canada\u2011China operating footprint positions it to pursue CDx opportunities across both regulated markets.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding diagnostic adoption and clinical deployment of Fandekang alongside eratrectinib. Actual results may differ due to risks including hospital adoption, reimbursement, and testing volume uptake.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.&#8216;s (a genetic cancer testing service&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72375,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,22],"tags":[574,15,573],"class_list":["post-72374","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-geneseeq","tag-product-approvals","tag-vcare-pharmatech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Approves Geneseeq&#039;s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech&#039;s Eratrectinib - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.&#039;s (a genetic cancer testing service provider operating in Canada and China) Fandekang NTRK1\/2\/3 gene fusion detection kit as a companion diagnostic (CDx) for eratrectinib, a next\u2011generation highly selective TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72374\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Approves Geneseeq&#039;s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech&#039;s Eratrectinib\" \/>\n<meta property=\"og:description\" content=\"The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.&#039;s (a genetic cancer testing service provider operating in Canada and China) Fandekang NTRK1\/2\/3 gene fusion detection kit as a companion diagnostic (CDx) for eratrectinib, a next\u2011generation highly selective TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72374\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-12T05:54:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-12T05:54:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1206.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Approves Geneseeq&#8217;s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech&#8217;s Eratrectinib\",\"datePublished\":\"2026-08-12T05:54:39+00:00\",\"dateModified\":\"2026-08-12T05:54:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374\"},\"wordCount\":410,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1206.webp\",\"keywords\":[\"Geneseeq\",\"Product approvals\",\"Vcare PharmaTech\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72374#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72374\",\"name\":\"NMPA Approves Geneseeq's Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech's Eratrectinib - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1206.webp\",\"datePublished\":\"2026-08-12T05:54:39+00:00\",\"dateModified\":\"2026-08-12T05:54:40+00:00\",\"description\":\"The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.'s (a genetic cancer testing service provider operating in Canada and China) Fandekang NTRK1\\\/2\\\/3 gene fusion detection kit as a companion diagnostic (CDx) for eratrectinib, a next\u2011generation highly selective TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72374\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1206.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1206.webp\",\"width\":1080,\"height\":608,\"caption\":\"NMPA Approves Geneseeq's Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech's Eratrectinib\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72374#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Approves Geneseeq&#8217;s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech&#8217;s Eratrectinib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Approves Geneseeq's Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech's Eratrectinib - Insight, China&#039;s Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.'s (a genetic cancer testing service provider operating in Canada and China) Fandekang NTRK1\/2\/3 gene fusion detection kit as a companion diagnostic (CDx) for eratrectinib, a next\u2011generation highly selective TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72374","og_locale":"en_US","og_type":"article","og_title":"NMPA Approves Geneseeq's Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech's Eratrectinib","og_description":"The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.'s (a genetic cancer testing service provider operating in Canada and China) Fandekang NTRK1\/2\/3 gene fusion detection kit as a companion diagnostic (CDx) for eratrectinib, a next\u2011generation highly selective TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd.","og_url":"https:\/\/flcube.com\/?p=72374","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-12T05:54:39+00:00","article_modified_time":"2026-08-12T05:54:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1206.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72374#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72374"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Approves Geneseeq&#8217;s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech&#8217;s Eratrectinib","datePublished":"2026-08-12T05:54:39+00:00","dateModified":"2026-08-12T05:54:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72374"},"wordCount":410,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=72374#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1206.webp","keywords":["Geneseeq","Product approvals","Vcare PharmaTech"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72374#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72374","url":"https:\/\/flcube.com\/?p=72374","name":"NMPA Approves Geneseeq's Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech's Eratrectinib - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=72374#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=72374#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1206.webp","datePublished":"2026-08-12T05:54:39+00:00","dateModified":"2026-08-12T05:54:40+00:00","description":"The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.'s (a genetic cancer testing service provider operating in Canada and China) Fandekang NTRK1\/2\/3 gene fusion detection kit as a companion diagnostic (CDx) for eratrectinib, a next\u2011generation highly selective TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72374#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72374"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=72374#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1206.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1206.webp","width":1080,"height":608,"caption":"NMPA Approves Geneseeq's Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech's Eratrectinib"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72374#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Approves Geneseeq&#8217;s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech&#8217;s Eratrectinib"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1206.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72374"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72374\/revisions"}],"predecessor-version":[{"id":72376,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72374\/revisions\/72376"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/72375"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}